CIK 0001374690
- Non-accelerated filer
- Smaller reporting company
Larimar Therapeutics, Inc.
Sign in to watch- Ticker
- LRMR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203857670
- Phone
- +1 844-511-9056
- Business address
- THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
- Former names
- ZAFGEN, INC., ZAFGEN INC
- Open-market buys, last 90 days
- $392,144
- in 8 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$392,144. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 30 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-06-21 | Heller Frances K Director | Grant or award · Stock Option (Right to Buy) | +14,500 | 14,500 | ||
| 2017-06-21 | PEREZ ROBERT J Director | Grant or award · Stock Option (Right to Buy) | +14,500 | 14,500 | ||
| 2017-05-11 | Hughes Thomas E. President and CEO | Option exercise | +18,928 | $0.75 | $14K | 83,088 |
| 2017-05-11 | Hughes Thomas E. President and CEO | Option exercise | +6,210 | $0.75 | $5K | 89,298 |
| 2017-05-11 | Hughes Thomas E. President and CEO | Option exercise | +68,073 | $0.82 | $56K | 157,371 |
| 2017-05-11 | Hughes Thomas E. President and CEO | Option exercise · Stock Option (Right to Buy | −18,928 | 0 | ||
| 2017-05-11 | Hughes Thomas E. President and CEO | Option exercise · Stock Option (Right to Buy) | −6,210 | 0 | ||
| 2017-05-11 | Hughes Thomas E. President and CEO | Option exercise · Stock Option (Right to Buy) | −68,073 | 0 | ||
| 2017-05-11 | KIM DENNIS D Chief Medical Officer | Purchase | +9,800 | $4.40 | $43K | 11,443 |
| 2017-05-10 | KIM DENNIS D Chief Medical Officer | Purchase | +200 | $4.40 | $880 | 1,643 |
| 2017-02-13 | Booth Bruce Director | Grant or award · Stock Option (Right to Buy) | +12,003 | 12,003 | ||
| 2017-02-13 | PEREZ ROBERT J Director | Grant or award · Stock Option (Right to Buy) | +13,289 | 13,289 | ||
| 2017-02-13 | Daniel Thomas O Director | Grant or award | +10,765 | $4.18 | $45K | 10,765 |
| 2017-02-13 | McDonough Cameron Geoffrey Director | Grant or award · Stock Option (Right to Buy) | +13,718 | 13,718 | ||
| 2017-02-13 | Barrett Peter Director | Grant or award · Stock Option (Right to Buy) | +24,864 | 24,864 | ||
| 2017-02-13 | LAMATTINA JOHN L Director | Grant or award | +11,363 | $4.18 | $47K | 11,363 |
| 2017-01-27 | Hughes Thomas E. President and CEO | Grant or award · Stock Option (Right to Buy) | +319,000 | 319,000 | ||
| 2017-01-27 | Allen Patricia L Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +88,000 | 88,000 | ||
| 2017-01-27 | KIM DENNIS D Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +88,000 | 88,000 | ||
| 2016-12-19 | Heller Frances K Director | Purchase | +10,000 | $3.23 | $32K | 30,000 |
Page 10 of 15 · 296 trades